$0.78
2.26%
Nasdaq, Apr 21, 08:17 pm CET
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Cue Biopharma, Inc. Stock price

$0.76
-0.19 19.79% 1M
-0.35 31.35% 6M
-0.33 30.09% YTD
-0.87 53.25% 1Y
-3.53 82.24% 3Y
-18.05 95.95% 5Y
-10.87 93.45% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.02 2.18%
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Key metrics

Market capitalization $47.11m
Enterprise Value $33.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.61
P/S ratio (TTM) P/S ratio 5.07
P/B ratio (TTM) P/B ratio 2.69
Revenue growth (TTM) Revenue growth 69.16%
Revenue (TTM) Revenue $9.29m
EBIT (operating result TTM) EBIT $-41.59m
Free Cash Flow (TTM) Free Cash Flow $-36.40m
Cash position $22.46m
EPS (TTM) EPS $-0.75
P/S forward 9.66
EV/Sales forward 6.88
Short interest 1.39%
Show more

Is Cue Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Cue Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Cue Biopharma, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Cue Biopharma, Inc. forecast:

Buy
100%

Financial data from Cue Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
9.29 9.29
69% 69%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
16% 16%
129%
- Research and Development Expense 36 36
10% 10%
391%
-39 -39
19% 19%
-422%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -42 -42
20% 20%
-448%
Net Profit -41 -41
20% 20%
-438%

In millions USD.

Don't miss a Thing! We will send you all news about Cue Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cue Biopharma, Inc. Stock News

Neutral
Seeking Alpha
6 days ago
Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Business Officer Operator Good day, and welcome to the Cue Biopharma Business Update Call. All participants are in a listen-only mode.
Neutral
GlobeNewsWire
7 days ago
Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developi...
Neutral
GlobeNewsWire
7 days ago
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and ac...
More Cue Biopharma, Inc. News

Company Profile

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Daniel Passeri
Employees 41
Founded 2014
Website www.cuebiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today